

1 **Clinico-microbiological profile and treatment outcomes in patients with isoniazid**
2 **monoresistant tuberculosis in South India**

3
4 Venkata Prasanna M¹., Muthuraj R²., Vimal Raj R¹., Govindarajan S³, Pajanivel R*¹

5
6 1 Department of Respiratory Medicine, MGMCRI, Puducherry, 607402, INDIA.

7 2 Intermediate Reference Laboratory, Puducherry,

8 3.State Tuberculosis unit Officer , Puducherry

9
10 **ABSTRACT**

11
12 Isoniazid (INH) is an important first-line medication for the treatment of tuberculosis.
13 The impact that tuberculosis drug resistance has on treatment outcomes is a topic that
14 is receiving a lot of attention these days because of the rising incidence of INH-
15 resistant cases. Study involves a single group of patients who have been diagnosed
16 with Isoniazid monoresistant tuberculosis. Treatment history and demographic data
17 of the patients were obtained after informed consent. The mutation patterns of
18 isoniazid were observed after multiplex PCR and Line Probe Assay (LPA). A total of
19 101 patient (M,F) records at the IRL, Puducherry were analyzed. The predominant
20 gene responsible for TB was KATG (67.3%). The KATG Mut1 was a prime mutation
21 observed in the present study population (58.41%). Study showed positive association
22 with males (74%), occupation as coolie (88%), diabetes as comorbidity (33%),
23 pulmonary tuberculosis as the TB site (98.01%), history of previous ATT intake in 43
24 patients (42.6%), katG mutation (67.3%), katG Mut 1 was the prime mutation
25 (58.4%).The cure rate was high in *INH high concentration resistance* patients which
26 was statistically significant (p=0.0167). INH monoresistance mutations seen in
27 64.3% of the patients with katG, compared to inhA (34.65%). Similar to katG
28 mutations, inhA mutations also have MUT1 as their most frequent gene pattern. There
29 is a significant association between males, diabetes, smoking and alcohol addictions
30 were associated with high risk of developing high dose INH monoresistance (katG).
31 High prevalence of recurrent tuberculosis was seen in high dose INH monoresistance
32 tuberculosis. Patients who are microbiologically confirmed pulmonary tuberculosis
33 and diabetes with rifampicin sensitive status needs to be checked for LPA for
34 isoniazid sensitivity status to prevent treatment failure and relapse. It is crucial to
35 understand the gene pattern in each of these patients since these mutations are closely
36 associated to high or low-degree resistance to INH

37 **Keywords:** INH-resistant, LPA, ATT, katG, inhA, Tuberculosis

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38

39 INTRODUCTION

40

41 One of the leading causes of death in developing and underdeveloped
42 Countries is Tuberculosis (TB), which is caused by the bacteria *Mycobacterium*
43 *tuberculosis* (MTB). According to the most recent statistics provided by the World
44 Health Organization (WHO), there were 6.4 million newly diagnosed cases of
45 Tuberculosis in the year 2021, a drop in incidence attributed to under reporting due
46 to covid 19 pandemic [1] although TB most frequently affects the lungs, it is also
47 capable of affecting other areas of the body. The incidence of TB is higher in India
48 and claims the lives of over half a million people [2]. Today, India has the highest
49 number of cases of MDR-TB in the world and is responsible for one-fourth of the
50 worldwide burden of the disease and has much lower success rates [3]. There is
51 evidence that tuberculosis is gradually decreasing, the worldwide emergence and
52 spread of Multi Drug Resistance (MDR) have become a major obstacle [4]. The
53 impact of Tuberculosis drug resistance and treatment outcomes has been a cause of
54 concern in the past few years because of the rise in incidence of INH-resistant.
55 However, new data indicates that more than half of patients with INH-mono-resistant
56 TB may require a treatment course lasting more than 6 months [5]. Additionally,
57 numerous reports have mentioned significantly varied treatment plans for INH
58 mono-resistant TB [6]. Mutations in *katG* or *InhA* regulatory genes are major genes
59 responsible for INH resistance. Catalase peroxidase, an enzyme that changes INH into
60 its physiologically active form, is encoded by the *katG* gene. INH was ineffective for
61 treating *Mycobacterium tuberculosis* with this mutation profile because *katG*
62 mutations, particularly those at codon 315, provide high levels of INH resistance. The
63 principal target of active INH, nicotinamide adenine dinucleotide dependent enoyl-
64 acyl carrier protein reductase, as well as ethionamide (ETH) and prothionamide, are

65 all encoded by the *InhA* regulatory region (PTH) [8] . High doses of INH may be
66 effective against *M. tuberculosis* with *InhA* mutations result in low-level resistance to
67 the medication [9]. The critical concentrations of INH resistance were categorized as
68 low and high dose with cut off values <0.2 3g/ml and >1 g/ml respectively. Low and
69 high concentration INH resistance can be viewed of as two separate entities because
70 different genetic changes are assumed to be the cause of each [10].

71

72 Line probe assay (LPA) was developed in response to the MDR-TB crisis in
73 the world and to identify drug resistance in TB patients. Through the National
74 tuberculosis elimination program, LPA is a quick method based on polymerase chain
75 reaction (PCR) that is used to identify *Mycobacterium tuberculosis* complex as well
76 as drug sensitivity to rifampicin (RPM), isoniazid (INH) and other first line drugs.
77 LPA only examines sputum samples that have an AFB smear positive result [11].
78 Comparing MDR-TB treatment to non-MDR-TB treatment, unsatisfactory outcomes
79 were more connected with MDR-TB treatment [12]. WHO has established a brief
80 treatment regimen for MDR-TB patients in an effort to overcome some of these
81 issues [13]. Numerous studies have been conducted in different nations to identify
82 the factors that affect MDR-TB treatment outcomes in both the general population
83 and particular target populations, including adults, children, with comorbidities and
84 those who have co-infected with HIV. These investigations have revealed that there
85 are significant regional differences in the predictors of treatment outcome. Body Mass
86 Index (BMI) >18.5kg/m², use of more than four effective medications, a negative
87 baseline sputum smear, and experiencing a surgical resection are some of the
88 variables that were discovered to be related with favourable treatment outcomes [14].
89 Other factors which included the use of linezolid [15] or fluoroquinolones,
90 customized treatment,[16] getting any help from the TB program, having more

91 understanding about the disease, and having more faith and support from nurses and
92 Physicians [9]. Other factors were co-infection with HIV, a positive smear at the
93 beginning of therapy, a history of TB treatment, smoking, pre-XDRTB, age >44
94 years, Ofloxacin resistance, male sex, low body weight at diagnosis (40 kg), poor
95 treatment adherence, smear positive at the second month of treatment, the use of
96 conventional medicine, and treatment interruptions longer than 14 days [17-19].
97 Contradictory results have been found for some of the above-mentioned criteria in
98 trials with unsatisfactory treatment outcomes, though [20] furthermore, there are still
99 gaps in the literature regarding the differences between patients with low- and high-
100 concentration monoresistant TB in terms of baseline traits, therapeutic regimen, side
101 events, and outcomes [9]. In the present investigation, it is proposed a) to study the
102 clinical profile of patients registered for Drug-Resistant Tuberculosis treatment
103 within Puducherry tuberculosis unit by review of treatment registry. (b). To study the
104 Isoniazid drug resistance pattern and the pattern of resistance mutation in these
105 patients by review of Intermediate Reference laboratory (IRL) registry. ©. To assess
106 the treatment outcomes of the INH monoresistant cases as recorded in the DR-TB
107 treatment registry. (d). To correlate the clinical and microbiological profiles with
108 treatment outcomes among patients with Isoniazid monoresistant tuberculosis within
109 the Puducherry tuberculosis unit.

110

111 **Materials and methods**

112

113 **Study design & Population**

114 It is a retrospective record-based study of 100 patients. Patients who had been
115 enrolled in IRL and DRTB registry to have Isoniazid monoresistant pulmonary
116 tuberculosis in Intermediate Reference laboratory, Puducherry. Study involves single
117 group of patients who were diagnosed with Isoniazid monoresistant tuberculosis.

118 **Eligibility criteria**

119 *Inclusion criteria* : All the patients who were registered in Intermediate reference
120 laboratory and Drug resistant tuberculosis registry as Isoniazid mono-resistant
121 tuberculosis. Patients who had been registered to have mutations in katG gene and
122 inhA gene.

123 *Exclusion criteria* : Patients who had been already diagnosed to have Poly Drug-
124 Resistant Tuberculosis, Multi-Drug Resistant Tuberculosis, and Extensive Drug
125 Resistant Tuberculosis. Patient records with incomplete information for the study

126 *Sample Size* . All Isoniazid mono-resistant patients with above-mentioned inclusion
127 criteria enrolled in Intermediate reference lab (IRL) from 2014- 2020.

128 **Minimum sample size is calculated to be 97** using the below mentioned formula.

129 $n = (Za)^2[p*q]$

130 -----

131 $d^2za = 1.96$

132 Estimated proportion (p)=0.5, q=1-p 1-0.5 =0.5

133 Estimated error (d)=10% (0.1)

134 **Sample size (n) =97**

135 **Study Tools**

136 To assess phenotype and genotype characteristics of patients diagnosed with
137 Isoniazid mono-resistant tuberculosis, treatment regimens, treatment failure with the
138 standard regimen and further how many were labelled from Isoniazid mono-resistant
139 tuberculosis to poly resistant tuberculosis, multidrug resistance and extensive drug
140 resistant tuberculosis.

141

142

143 **Method of Data Collection**

144 Patients diagnosed with Isoniazid mono-resistant tuberculosis were identified by the
145 collection of data from Intermediate reference laboratory and drug resistant
146 tuberculosis registry, Puducherry. Baseline characteristics/parameters to be included
147 are as follows:

- 148 · Sex
- 149 · Age
- 150 · Comorbidities
- 151 · Smear positive Status
- 152 · Genes associated with the resistance
- 153 · Type of resistance – low and high dose Isoniazid resistance.
- 154 · History of treatment- new and previously treated. Previously treated case can be
155 relapse (recurrent), failure or default (treatment after default).
- 156 · Radiographic Findings – Cavitary lesion, Bilateral lesion, Extensive lesion.

157 Treatment success and failure in each of the above Characteristics/Parameters.
158 Data will be entered on Microsoft Excel sheets, checked for accuracy and
159 completeness, and statistically analyzed to evaluate the significance of each risk factor
160 in the development of Isoniazid monoresistant pulmonary tuberculosis.

161 **Data Processing and Statistical Analysis**

162 The data was entered with an excel sheet. Data was exported to Medcalc version
163 19.2.6 [21] for further processing. All categorical variables were expressed as
164 percentages and the continuous variables were expressed as mean \pm standard
165 deviation. The statistical significance of mean differences was compared in two
166 groups using an independent t test and categorical variables were analysed using chi
167 square test. All values were considered significant if the *p*-value was < 0.05 .

168 **Ethical Consideration**

169 This research was strictly fulfilling the ethical guidelines as outlined in the
170 declaration of Helsinki, participants signed a consent form, and were assured that their
171 participation was completely voluntary and could be terminated at any time without
172 compromising their medical care. The study protocol was approved by the Mahatma
173 Gandhi Medical College & Research Institute (MGMCRI) Review board.

174

175 **RESULTS**

176

177 **Demographic and Clinical Characteristics of Patients**

178

179 A total of 101 patients diagnosed with Isoniazid mono-resistant tuberculosis were
180 identified by the collection of data from the Intermediate reference laboratory and
181 drug resistance tuberculosis registry, Puducherry from 2014-2020 was included in the
182 study. The baseline demographics and clinical characteristics of these patients are
183 listed in Table 1.

184 **Age.** The study participants mean age was 44.6 ± 15.3 years and ranged from 14 to 87
185 years. The predominant age group was between 40 to 50 years (Fig.1A.a).

186 **Gender .**The predominant gender was male (74%) and followed by the female (26%)
187 observed in the study (Fig.1A b)

188 **Height .** The average height of the study participants was 159.5 ± 7.22 cm and ranged
189 from 140 to 174 cm (Fig1A c)

190 **Weight .**The weight of the study population was ranged from 17 to 75 kg with
191 average of 48.6 ± 11.5 kg. It showed that majority of the participants were lean body
192 weight (Fig.1A d).

193 **Body mass index (BMI).** The average BMI was 18.87 ± 4.51 kg/m² which showed a
194 normal range. However, around 28 % of patients who had below normal BMI were
195 observed in the study (Fig1A e).

196 **Blood glucose.** The blood glucose levels (Fig.1A f) were determined and found that
197 the fasting blood glucose levels were higher (177.93 ± 82.50 mg/dl) than random blood
198 glucose levels (159.27 ± 90.04 mg/dl)

199 **Marital status.** In the present study, the majority of the study population was married
200 (93%) followed by 4% and 3 % of patients who were single and unmarried
201 respectively (Fig1B a)

202 **Occupation .** The predominant study population belongs to coolie (88%) followed by
203 students (6%) and house-wife (4%). The remaining doctor and salesman were 1%
204 each (Fig1B b)

205 **Addictions.** Smoking was found to be associated in 45% of the patients. Alcoholism
206 was found in 50 % patients. No addictions was found in 15% patients. (Fig1B c)

207
208 **Co-morbidities.** *Diabetes mellitus* was the only co-morbidity observed in this study
209 which was 33.67% , systemic hypertension 20.97%, coronary artery disease 6% and
210 others 4% of the study population did not have any co-morbidities (Fig.1B d)

211 **TB Site.** In the study population, the majority of the patients had pulmonary
212 tuberculosis (98.01%) and 1.98% of the population had extrapulmonary tuberculosis
213 (Fig.1B e)

214 215 **Clinical Characteristics of the study population**

216 **History of anti-tuberculosis treatment .** The history of previous ATT was observed
217 in 43 patients (42.6%). Among 43 patients, sputum positive at diagnosis and
218 retreatment was found in 31 patients (72.1%). Besides, 58 patients (57.4%) did not
219 have any previous history of ATT.

220 **Gene responsible.** The gene responsible for INH monoresistant TB were KAT G
221 (67.3%) and INH A (32.7%) of patients (Fig.2 a)

222 **Mutation Pattern.** The katG Mut1 was a prime mutation observed in the present
223 study population (58.41%). Besides, inhA Mut1 was found in 23.76%, inhA Mut1
224 present & WT1 absent in 7.9%, katG Mut1 present & WT1 absent in 6.9%, and other
225 mutations were observed in 2.97% (Fig.2 b)

226 **Comparison of clinico-microbiological profile in INH low and high concentration**
227 **resistance**

228 The clinico-microbiological parameters were compared with the low and high
229 levels of INH mono-resistance listed in table 2. The mean age of the patients with
230 low- and high-concentration mono-resistant TB were 44.54±14.68 and 44.59±15.80
231 years respectively. It showed statistically not significant (P=0.9881) (Fig.2 c). Male
232 gender was 68.6% and 75.75% in low- and high-concentration mono resistant TB
233 respectively. The male gender was significantly higher in high concentration mono-
234 resistant TB (p=0.0025) (Fig.15). Besides, the female gender was not significantly
235 differed between the two groups of patients (p=0.3359). The average height of low
236 and high concentration mono-resistant TB was 159.20±8.51 and 159.68±6.53
237 respectively. Between both groups, the mean height was almost the same and was not
238 statistically significant (p= 0.7772) (Fig.2 d)

239 The mean weight of low and high-concentration mono-resistant TB did not
240 show any statistically significant difference (p=0.4142) (Fig.2 e). The mean body
241 mass index (BMI) in low concentration mono-resistant TB was 18.82±5.42 and in
242 high concentration mono-resistant TB was 18.9±4.02. The BMI in both groups has
243 shown almost similar which was statistically no significant difference (p=0.9407)
244 (Fig.3 a).

245 The previous history of ATT was higher in high concentration resistance than in
246 low concentration which was statistically significant (p=0.0474) (Fig.3 b). Smoking

247 and alcoholism as addiction history was predominant and significantly higher in high
248 concentrations than in low concentrations ($p=0.0373$) (Fig.3 c). The occurrence of TB
249 in the pulmonary region was predominant and significantly higher in high
250 concentrations than in low concentrations ($p=0.0002$) (Fig.3 d).

251

252 **Pattern of Gene mutation**

253 The most common mutation in INH-resistant strains was in the *katG* gene
254 (64.35%) followed by *inhA* gene (34.65%). In 1 (1%) patient, both *inhA* and *katG*
255 gene mutations were observed (Table 3 & Fig.4). Comparing the pattern of gene
256 mutations in INH monoresistant strains revealed that of 35 isolates with only *inhA*
257 gene mutation, WT1 pattern was absent and MUT1 present in 8 (22.9%) strains, WT2
258 pattern was absent and MUT1 present in 3 (8.6%), while MUT1 pattern was present
259 in 24 (68.6 %) strains. *KatG* gene mutation patterns were observed in 66 isolates with
260 different sequences. WT1 was absent and MUT1 was present in 6 (9.1%), *inhA*WT2
261 was absent and *inhA* MUT1 was present in 1 (1.5 %), MUT1 was seen in 58 (87.9%)
262 patients (Table 4).

263 **Treatment outcome**

264 Out of 101 INH monoresistant tuberculosis patients, 35 had low-dose concentration
265 resistance (*inhA*), of which 28 patients were cured. 66 patients had high dose
266 resistance (*katG*), of which 49 patients were cured. Cure rate was high in *INH high*
267 *concentration resistance* patients which were statistically significant ($p=0.0167$)
268 (Fig.5)

269 **Treatment impact on weight**

270 The treatment impact on patients' weight was determined and found that weight gain
271 was a major outcome in both low and high concentrations (Table 6). However, the
272 weight gain was not statistically significant ($p=0.0622$) (Fig.6 A). Similarly, the

273 weight loss was also statistically not significant ($p=0.7247$) (Fig.6 B). Besides, there
274 were no changes in weight after treatment was observed in some patients but it was
275 not significantly differed.

276 **DISCUSSION**

277
278 As a result of its effective early bactericidal activity against rapidly
279 proliferating cells, isoniazid is a crucial first-line anti-TB medication [22]. Isoniazid
280 helps to prevent the selection and formation of a drug-resistant TB population when
281 used in combination with other anti-TB medications. But among all first-line
282 medications, isoniazid resistance is the most prevalent, with an estimated frequency of
283 13% globally, including new and retreatment cases [23]. It is still unknown what the
284 best treatment plan is for isoniazid mono-resistant TB. According to several recent
285 studies, [24,25] individuals with isoniazid mono-resistant TB fared worse than those
286 with drug-susceptible TB, despite studies from the 1970s and 1980s reporting a low
287 rate of treatment failure for those receiving four or five medications over a six month
288 period.

289 According to the results of the current investigation, *Diabetes mellitus* affected
290 33% of the patients. Recently, West Bengal study [26] found that 43% of TB
291 patients also had diabetes. A study conducted in Indonesia, Peru, South Africa and
292 Romania with a high TB burden found that 12.5% of TB patients had diabetes [27].
293 The WHO strategy of routine bidirectional symptom-based TB screening in known
294 DM patients in high TB burden countries has been endorsed by Alisjahbana et al.[28].
295 In our current study Diabetes patients having 54 history of previous tuberculosis and
296 ATT intake are having high dose isoniazid monoresistance (katG). The people who
297 had arrived for the presumed TB test were overwhelmingly male. Male patients made
298 up 74% of those with MTB positivity. Our results are in line with those of recent

299 studies in India that found that 76%, 75%, 70.5%, 71%, and 72% of TB patients were
300 males, as reported [29-32] . According to the WHO study from 2021, adult males,
301 who made up 56% of all TB cases in 2019, have the highest prevalence of the disease
302 [6]. More than one gene or gene complex, including the katG, inhA, and kasA genes
303 as well as the intergenic region of the oxyR ahpC complex, may be altered in the
304 genetic foundation of INH resistance [33]. Two genes, katG and inhA, have probes
305 that can be used to identify INH resistance in Genotype MTBDR +. According to Van
306 Rie et al.,[34] the katG mutation was less common (37.6%). Numerous studies have
307 demonstrated a correlation between high and low levels of INH resistance and the
308 codon 315 of the katG gene (50%–90%) and regulatory region of the inhA gene
309 (20%– 35%), respectively[35]. In our study we found that the katG gene (67% of
310 patients had this mutation), followed by the inhA gene (33% of patients). Yao et al.
311 (2010) obtained results that were almost identical. A 50 INH monoresistant patients
312 were examined, and it was found that 41 (82%) had KatG mutations and 9 (18%) had
313 inhA mutations [36]. In addition, according to Huyen et al., 28.2% and 75.3%,
314 respectively, of the population, contained mutations in the inhA promoter region [37].
315 Similar findings were made by Kigozi et al. (2018) who found that 6% of samples
316 had inhA mutations and 80% had katG mutations [38].

317 In addition, Tavakkoli and Nazemi (2018) reported that inhA genes and katG
318 genes, respectively, were in charge of INH resistance in 17.24% and 82.76% of the
319 strains [39]. Niehaus et al. discovered that 33.1% of 924 isolates, or 30.3% of those
320 with MDR TB, 47.2% of those with pre-XDR-TB, and 82.8% of those with XDR-
321 TB, carried an inhA mutation with or without a katG mutation [40] . Alagappan et al.
322 (2018) looked into the promoter region of the inhA gene and codon katG for INH
323 resistance mutations in M. tuberculosis. Of the 15,438 INH resistant bacteria, 1,821

324 (11.8%) showed detectable mutations, with 71.0% occurring in katG315 and 29.0% in
325 the inhA promoter region[41]. Isakova et al. (2018) found that the katG gene was
326 mutated in 91.2% of strains, the inhA gene was mutated in 7% of specimens, and the
327 ahp C gene was mutated in 2 more specimens (1.8% of the total) [42]. Jagielski et al.
328 (2015) also noted that katG mutations were present in 85.2% of MDR patients.
329 Approximately 3.7% of the 54 patients had only one inhA mutation, and the
330 remaining patients, or 11.1%, had both mutations [43]. A comparative outcomes are
331 shown in Table 7 .

332 Clinicians should be aware of mutations in the katG or inhA promoter
333 region.[44] and high level of resistance to INH is indicated by the existence of
334 mutations in katG alone or in conjunction with inhA. For these patients, adding even
335 high doses of INH is unlikely to improve the efficacy of a regimen. On the other hand,
336 a mutation restricted to inhA is typically associated with a low level of INH resistance,
337 and these people are likely to benefit from large doses of INH (10–15 mg/kg/day)
338 [45]. Results of our study showed mean age of incidence with low- and high
339 concentration mono-resistant TB were 44.54 ± 14.68 and 44.59 ± 15.80 years
340 respectively. It showed statistically not significant ($p=0.9881$). Besides, the male
341 gender was 68.6% and 75.75% in low-and high-concentration mono-resistant TB
342 respectively. The average height of the study participants was 159.5 ± 7.22 cm and
343 ranged from 140 to 174 cm. The weight of the study population was ranged from 17
344 to 75 kg with average of 48.6 ± 11.5 kg. It showed that majority of the patients in the
345 study had low BMI. The predominant study population belongs to coolie (88%)
346 followed by students (6%) and housewife (4%). The remaining doctor and salesman
347 were 1% each. *Diabetes mellitus* was the most common co-morbidity observed in this
348 study which was 33% in the population. Smoking and alcohol association was

349 associated with patients diagnosed with high dose INH monoresistant tuberculosis
350 (53.03%) of which significant of the patients were associated with retreatment
351 (68.57%). In the study population, most of the patients had pulmonary tuberculosis
352 (98.01%) and 1.98% of the population had extrapulmonary tuberculosis (pleural
353 effusion). The history of previous ATT was observed in 43 patients (42.6%). Among
354 43 patients, sputum positive at diagnosis and retreatment was found in 31 patients
355 (72.1%). Besides, 58 patients (57.4%) did not have any previous history of ATT. INH
356 high dose monoresistance was seen in 66 patients and low dose mono resistance was
357 58 seen in 35 patients. The predominant gene responsible for TB was katG (64.3%)
358 and inhA gene was observed in 34.65% of patients. The katG Mut1 was a prime
359 mutation observed in the present study population (58.41%). Besides, inhA Mut1 was
360 found in 23.76%, inhA Mut1 present & WT1 absent in 7.9%, katG Mut1 present &
361 WT1 absent in 6.9%, and other mutations were observed in 2.97%. Treatment
362 outcomes showed 77 patients were cured (74.75%), 17 patients were lost to follow up
363 (16.5%), 3 patients died during the course of treatment (2.91%), treatment failure was
364 seen in 2 patients (1.94%), treatment regimen changed in 1 patient (0.97%). Study
365 showed positive association with males (74%), occupation as coolie (88%), diabetes
366 as comorbidity (33%), pulmonary tuberculosis as the TB site (98.01%), history of
367 previous ATT intake in 43 patients (42.6%), katG mutation (67.3%), katG Mut 1 was
368 the prime mutation (58.4%). Study also showed that male patients with diabetes has
369 comorbidity, with history of ATT intake along with sputum positive at diagnosis and
370 retreatment (72.1%) were associated with INH high dose monoresistance (katG),
371 having katG Mut 1 as prime mutation. The importance of treating physicians being
372 aware of these gene alterations as well as the usefulness of laboratories reporting
373 these mutations cannot be overstated.

374 **CONCLUSION**

375

376 Patients with both smoking and alcohol addictions were with INH high dose
377 monoresistance (katG), of which katG Mut 1 prime mutation was predominant
378 (53.03%). A 32 patients with history of previous tuberculosis were diagnosed to have
379 recurrent tuberculosis with high dose INH monoresistance out of which 27 had
380 diabetes, smoking and alcohol association (84.3%). Current study showed that there
381 is high prevalence of INH monoresistance in patients with previous H/O ATT intake,
382 alcohol, smoking and diabetes. Results of the study showed that there is a
383 significant association between males, diabetes, smoking and alcohol addictions were
384 associated with high risk of developing high dose INH monoresistance (katG)In
385 Pondicherry, due to effective screening, implementation of NTEP program and there
386 has been a rise in incidence of INH monoresistance tuberculosis in past few years
387 raising a concern for increase in risk of treatment failure and multi drug resistant
388 tuberculosis. Present study conclude that high prevalence of addictions, prevailing
389 low socioeconomic class had influence in treatment outcomes, incidence of recurrent
390 cases and high risk for development of INH monoresistance tuberculosis in
391 Puducherry. Patients who are microbiologically confirmed pulmonary tuberculosis
392 and diabetes with rifampicin sensitive status needs to be checked for LPA for
393 isoniazid sensitivity status to prevent treatment failure and relapse. It is crucial to
394 understand the gene pattern in each of these patients since these mutations are closely
395 associated to high or low-degree resistance to INH .

396

397

398

399

400

401

402

403 **Acknowledgments**

404

405

406 We would like to acknowledge Dr. Muthuraj R, chief microbiologist, Intermediate

407 reference laboratory, Puducherry, for his support in providing laboratory data and Dr

408 Ezhumali for his statistical assistance.

409

410 **Author Contributions**

411

412 **Conceptualization:** Pajanivel R, Venkata Prasanna M

413 **Data curation:** Venkata Prasanna M

414 **Formal analysis:** Pajanivel R, Venkata Prasanna M, Muthuraj R, Vimal Raj R

415 **Methodology:** Pajanivel R, Venkata Prasanna M, Muthuraj R

416 **Software:** Venkata Prasanna M

417 **Supervision:** Pajanivel R, Muthuraj R, Govindarajan S, Vimal Raj R

418 **Visualization:** Venkata Prasanna M, Pajanivel R, Muthuraj R, Govindarajan S, Vimal

419 Raj R

420 **Writing** –Venkata Prasanna M, Pajanivel R

421 **Original draft:** Venkata Prasanna M, Pajanivel R, Muthuraj R, Vimal Raj R

422 **Writing – review & editing:** Venkata Prasanna M, Pajanivel R, Muthuraj R,

423 Govindarajan S, Vimal Raj R

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439 References

440

441 1. Global tuberculosis report Oct.27, 2022 , [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/9789240013131)
442 [redirect/9789240013131](https://www.who.int/publications-detail-redirect/9789240013131)

443

444 2. Global Tuberculosis Report s July 14,2022, [https://www.who.int/teams/global-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports)
445 [tuberculosis-programme/tb-reports](https://www.who.int/teams/global-tuberculosis-programme/tb-reports)

446

447 3 713587265 Report_ITR workshop.pdf Jul 14,
448 2022 :[https://tbcindia.gov.in/WriteReadData/1892s/713587265Report_ITR%20works](https://tbcindia.gov.in/WriteReadData/1892s/713587265Report_ITR%20workshop_p.pdf)
449 [ho_p.pdf](https://tbcindia.gov.in/WriteReadData/1892s/713587265Report_ITR%20workshop_p.pdf)

450

451 4. Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic
452 resistance in *Mycobacterium tuberculosis*. *Int J Infect Dis*. 2015;32:94–100.

453

454 5. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura
455 LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-
456 mono-resistant tuberculosis. *Clin Infect Dis*. 2009; 48(2):179–85.

457

458 6. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among
459 tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. *Int J Tuberc*
460 *Lung Dis*. 2012;16(6):812–6.

461

462 7. Almeida Da Silva PEA, Palomino JC. Molecular basis and mechanisms of drug
463 resistance in *Mycobacterium tuberculosis*: classical and new drugs. *J Antimicrob*
464 *Chemother*. 2011; 66(7):1417–30.

465

466 8. Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, et al. Clinical
467 Characteristics and Treatment Outcomes of Patients with Low- and High
468 Concentration Isoniazid-Mono-resistant Tuberculosis. *PLOS ONE* 2014; ;9(1):e
469 86316.. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086316>

470

471 9..Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA.
472 Detection of *katG* and *inhA* mutations to guide isoniazid and ethionamide use for
473 drug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2016 ;20(8):1099–104.

474

475 10. Desikan P, Panwalkar N, Mirza SB, Chaturvedi A, Ansari K, Varathe R, et al.
476 Line probe assay for detection of *Mycobacterium tuberculosis* complex: An
477 experience from Central India. *Indian J Med Res*. 2017 ;145(1):70–3.
478 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460577/>

479

480 11. Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Ba Z, Naing NN. Treatment
481 Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared
482 with Non-MDR-TB Infections in Peninsular Malaysia. *Malays J Med Sci*.
483 2016 ;23(4):17–25.

- 484
485 12. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment
486 outcomes for HIV and MDR-TB co-infected adults and children: systematic review
487 and meta-analysis. *Int J Tuberc Lung Dis*. 2015;19(8):969–78.
488
- 489 13. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment
490 outcomes for HIV-uninfected patients with multidrug-resistant and extensively
491 drug-resistant tuberculosis. *Clin Infect Dis*. 2008 ;47(4):496–502.
492
- 493 14. Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment
494 outcomes of multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*.
495 2015;19(5):525–30.
496
- 497 15. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for
498 multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta
499 analysis of published studies. *Infectious Diseases of Poverty*. 2017;6(1):7.
500 <https://doi.org/10.1186/s40249-016-0214-x>
501
- 502 16 Tupasi TE, Garfin AMCG, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC,
503 et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-
504 Resistant Tuberculosis, the Philippines, 2012-2014. *Emerg Infect Dis*.
505 2016;22(3):491–502.
506
- 507 17. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment
508 Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi
509 Center Investigation. *PLOS ONE* 2013;8(12):e82943.
510 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082943>
511
- 512 18. Predictors of poor treatment outcome in multi- and extensively drug-resistant
513 pulmonary TB | *European Respiratory Society* 2022.
514 <https://erj.ersjournals.com/content/33/5/1085>
515
516
- 517 19. Periasamy A. Predictors of Outcome in Drug Resistant Tuberculosis Patients. *J*
518 *Pulm Respir Med* 2017;07(01). [https://www.omicsonline.org/open-
519 access/predictors-of-outcome-in-drug-resistant-tuberculosis-patients-2161-105X-
520 1000391.php?aid=86111](https://www.omicsonline.org/open-access/predictors-of-outcome-in-drug-resistant-tuberculosis-patients-2161-105X-1000391.php?aid=86111)
521
- 522 20. Elliott E, Draper HR, Baitsiwe P, Claassens MM. Factors affecting treatment
523 outcomes in drug-resistant tuberculosis cases in the Northern Cape, South Africa.
524 *Public Health Action* 2014;4(3):201–3.
525 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533815/>
526
- 527 21. MedCalc Statistical Software version 19.2.6 (MedCalc Software bv, Ostend,
528 Belgium; <https://www.medcalc.org>; 2020)"
529
530
- 531 22. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN,
532 et al. American Thoracic Society/Centers for Disease Control and
533 Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J*
534 *Respir Crit Care Med*. 2003 ;167(4):603–62.

535

536

537 23. Anti-tuberculosis drug resistance in the world : fourth global report 2022 Aug 28].
538 https://www.who.int/publications-detail_redirect/9789241563611

539

540 24 Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al.
541 Standardized treatment of active tuberculosis in patients with previous treatment
542 and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.
543 PLoS Med. 2009 ;6(9):e1000150.

544

545 25. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G. Treatment
546 outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public
547 Health 2005 ;5(1):14. <https://doi.org/10.1186/1471-2458-5-14>

548

549

550 26. Kundu S, Sikder R, Dey R, Majumdar K, Joardar G. Study of socio demographic
551 and treatment profile and other epidemiological correlates of clients attending revised
552 national tuberculosis control programme clinic in a tertiary hospital of West Bengal,
553 India. International Journal Of Community Medicine And Public Health. 2020
554 1;7:742–7.

555

556 27. Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC,
557 Malherbe ST, et al. Diabetes Mellitus Among Pulmonary Tuberculosis Patients
558 88From 4 Tuberculosis-endemic Countries: The TANDEM Study. Clin Infect Dis.
559 2020;70(5):780–8.

560

561 28. Alisjahbana B, McAllister SM, Ugarte-Gil C, Panduru NM, Ronacher K,
562 Koesoemadinata RC, et al. Screening diabetes mellitus patients for pulmonary
563 tuberculosis: a multisite study in Indonesia, Peru, Romania and South Africa. Trans
564 R Soc Trop Med Hyg. 2021;115(6):634–43.

565

566 29. Mathur RB, Shukla US, Bindal HK. Role of cartridge-based nucleic acid
567 amplification test to diagnose tuberculosis at tertiary care teaching hospital in
568 Rajasthan, India. International Journal of Research in Medical Sciences .
569 2019;7(11):4243–8. <https://www.msjonline.org/index.php/ijrms/article/view/7340>

570

571 30. Jethani S, Kakkar R, Semwal J, Rawat J. Socio- Demographic Profile of
572 Tuberculosis Patient: A Hospital Based Study at Dehradun. National Journal of
573 Community Medicine 2014;5(01):6–9.
574 <https://www.njcmindia.com/index.php/file/article/view/1303>

575

576 31. M S, Y SC, M R, D IG. Patient and health system delays in diagnosis and
577 treatment of tuberculosis patients in an urban tuberculosis unit of south India.
578 International Journal Of Community Medicine And Public Health. 2017;3(4):796–
579 804. <https://www.ijcmph.com/index.php/ijcmph/article/view/799>

580

581 32 S US, Kumar AMV, Venkateshmurthy NS, Nair D, Kingsbury R, R P, et al
582 Implementation of the new integrated algorithm for diagnosis of drug-resistant
583 tuberculosis in Karnataka State, India: How well are we doing? PLOS ONE

- 584 2021;16(1):e0244785.<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244785>
585
586
- 587 33. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to
588 isoniazid, rifampin, and pyrazinamide in *Mycobacterium tuberculosis*. *Respir Res.*
589 2001;2(3):164–8.
590
- 591 34. Van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD, Richardson M,
592 et al. Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of
593 *Mycobacterium tuberculosis* in a High-Incidence Community. *J Clin*
594 *Microbiol.*2001;39(2):636–41 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC87790/>
595
- 596 35. Miotto P, Piana F, Cirillo DM, Migliori GB. Genotype MTBDRplus: a Further
597 Step toward Rapid Identification of Drug-Resistant *Mycobacterium tuberculosis*. *J*
598 *Clin Microbiol* 2008;46(1):393–4.
599 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2224251/>
600
- 601 36. Yao C, Zhu T, Li Y, Zhang L, Zhang B, Huang J, et al. Detection of *rpoB*, *katG*
602 and *inhA* gene mutations in *Mycobacterium tuberculosis* clinical isolates from
603 Chongqing as determined by microarray. *Clin Microbiol Infect.* 2010; 16 (11):1639–
604 43.
605
- 606 37. Huyen MNT, Cobelens FGJ, Buu TN, Lan NTN, Dung NH, Kremer K, et al.
607 Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis
608 Treatment Outcomes. *Antimicrob Agents Chemother* . 2013;57(8):3620–7.
609 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719713/>
610
611
- 612 38. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, et al
613 Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations
614 in *Mycobacterium tuberculosis* isolates from Uganda. *PLOS ONE* .
615 2018;13(5):e0198091.
616 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198091>
617
618
- 619 39.. Tavakkoli Z, Nazemi A. Genotyping of Related Mutations to Drug Resistance in
620 Isoniazid and Rifampin by Screening of *katG*, *inhA* and *rpoB* Genes in
621 *Mycobacterium tuberculosis* by High Resolution Melting Method. *Mycobact Dis*
622 2018 ;08(03). Available from: [https://www.omicsonline.org/open-access/genotyping-](https://www.omicsonline.org/open-access/genotyping-of-related-mutations-to-drug-resistance-in-isoniazid-andrifampin-by-screening-of-katg-inha-and-rpob-genes-in-mycobacter-2161-1068-1000265-103777.html)
623 [of-related-mutations-to](https://www.omicsonline.org/open-access/genotyping-of-related-mutations-to-drug-resistance-in-isoniazid-andrifampin-by-screening-of-katg-inha-and-rpob-genes-in-mycobacter-2161-1068-1000265-103777.html) drug-resistance-in-isoniazid-andrifampin-by-screening-of-
624 *katg-inha-and-rpob* genes-in-mycobacter-2161-1068-1000265-103777.html
625
- 626 40. . Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JCM. High Prevalence of
627 *inhA* Promoter Mutations among Patients with Drug-Resistant Tuberculosis in
628 KwaZulu-Natal, South Africa. *PLOS ONE* 2015;10(9):e0135003.
629 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135003>
630
- 631 41. . Alagappan C, Sunil Shivekar S, Brammacharry U, Cuppusamy Kapalamurthy VR,
632 Sakkaravarthy A, Subashkumar R, et al. Prevalence of mutations in genes
633 associated with isoniazid resistance in *Mycobacterium tuberculosis* isolates from re-

634 treated smear-positive pulmonary tuberculosis patients: A meta-analysis. *J Glob*
635 *Antimicrob Resist.* 2018;14:253–9.

636

637 42.. Isakova J, Sovkhozova N, Vinnikov D, Goncharova Z, Talaibekova E, Aldasheva
638 N, et al. Mutations of *rpoB*, *katG*, *inhA* and *ahp* genes in rifampicin and isoniazid-
639 resistant *Mycobacterium tuberculosis* in Kyrgyz Republic. *BMC Microbiol.*
640 2018 ;18(1):22.

641

642 43. Jagielski T, Bakula Z, Roeske K, Kamiński M, Napiórkowska A, Augustynowicz-
643 Kopeć E, et al. Mutation profiling for detection of isoniazid resistance in
644 *Mycobacterium tuberculosis* clinical isolates. *J Antimicrob Chemother.*
645 201;70(12):3214–21.

646

647 44. Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary
648 tuberculosis in India: systematic review and meta-analysis. *BMC Public Health*
649 2017 ;17(1):817. <https://doi.org/10.1186/s12889-017-4779-5>

650

651 45. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the
652 WHO treatment guidelines for drug-resistant tuberculosis..
653 https://www.who.int/publications/i/item/9789241550079_9

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669





Figure 2: Gender distribution



670

671

A. Distribution of study population age

b. Gender

672



673



674

c. Normal plot for height distribution

d. Normal plot for weight distribution

675

676



677

e. Normal plot for BMI distribution

f. Blood glucose levels

678

679

680

Figure 1A. Demographics and clinical characteristics based on age, gender, height, weight, BMI and Glucose levels



681

682

683

684

685





686

687 *a. Marital status*

688 *b. Occupational profile*

689

690




691

692 *c. Addictions*

693 *d. Profile of Co-morbidities*

694

695



696


697 *e. TB Occurring site*

698

699 Figure 1B. Demographics and clinical characteristics based on marital status,
700 Occupational profile, addictions, profile of Co-morbidities and TB
701 occurring site

702



703
704
705
706



707

708 *Figure 2 a Responsible Gene distribution*



Figure2.b Mutation pattern



709

710 *Figure 2 c Comparison of Age between*
711 *Low & high-concentration mono-resistant*

Figure 2.d Comparison of gender between
low & high-concentration mono resistant TB



712

713 *Figure 2 e Comparison of height between low &*
714 *high-concentration mono-resistant TB*


Figure 2f Comparison of weight between
Low^ & high-concentration mono resistant TB

715

716

717

718 *Figure 2 Comparision of age, gender, height and weight between low & high*
719 *concentration mono-resistant TB*



720

721 *Fig.3 a. Comparison of BMI between low &*
722 *high-concentration mono-resistant*





Figure 3 b Comparison of History of ATT



723

Figure 3.c Addiction history




Figure 3 d Comparison of Pulmonary TB

724
725


726

727 *Figure 3. Comparison of BMI, ATT, Adiction and pulmanary TB*

728

729

730



731

732


733

734

735

736

Figure 4.A Pattern of gene mutations



737


738

739


740

Figure 4 B Treatment outcome between two groups

741



742



743 *Figure 5.A Comparison of weight gain*

744 *Figure 5.B Comparison of weight loss*

745

746

747

748

749

750

751

752

753

754

755

756

757


758

759

760

761

762



763

764 **Figure 6: Current study showing gene association with INH**
765 **mono-resistance**

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781 *Table 1: Baseline characteristics of the study population*

782

Characteristics	Mean± SD N (%)
Age in years	44.6±15.3
Gender (M:F)	75:26
Height in cm	159.5±7.22
Weight in kg	48.6±11.5
BMI kg/m ²	18.87±4.51
FBS	177.93±82.50
RBS	159.27±90.04
Marital Status	
Married	94 (93.06%)
Unmarried	07 (6.94%)
Comorbidities	
DM	33 (32.67%)
Systemic Hypertension	21 (20.79%)
Coronary artery disease	06 (5.94%)
TB Region	
Pulmonary	100 (98.01%)
Extrapulmonary	01 (1.98%)

783

784

785

786

787

788

789

790

791

792

793

794

795

796 *Table 2: Demographic and clinical characteristics of the patients*

Parameters	<i>INH low concentration resistance</i> N=35	<i>INH high concentration resistance</i> N=66	p Value
Age	44.54±14.68	44.59±15.80	0.9881
Male	24 (68.6%)	50 (75.75 %)	0.0025
Female	11 (31.4 %)	16 (24.24%)	0.3359
Height in cm	159.20±8.51	159.68±6.53	0.7772
Weight in kg	49.93±12.04	47.92±11.25	0.4142
BMI kg/m ²	18.82±5.42	18.9±4.02	0.9407
H/O ATT	15	28	0.0474
Alcoholism	6	18	0.0484
Smoking	4	10	0.0442
Smoking and alcohol	14	35	0.0213
Pulmonary tuberculosis	30	66	0.0002

797

798

799

800

801

802

803

804

805

806

807

808

809 *Table 3: Pattern of gene mutations in INH-resistant TB strains*

Gene	N	%
inhA	35	34.65
katG	65	64.35
Both	01	1

810
811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834 *Table 4: Analysis of patterns of gene mutations at various loci of InhA and*
835 *katG in Isoniazid Mono-resistant Tuberculosis Patients*

Gene	INH low concentration resistance N=35				INH high concentration resistance N=66			
	Locus							
	WT1(-)	WT2 (-)	MUT1 (+)	MUT2 (+)	WT1(-)	WT2 (-)	MUT1 (+)	MUT2 (+)
inhA	8	3	35	-		1	1	
KatG	-	-	-	-	6		60	

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856 *Table 5: Treatment outcome between two groups*

Treatment Outcome	<i>INH low concentration resistance</i> N=35	<i>INH high concentration resistance</i> N=66	<i>P value</i>
Cured	28	49	0.0167
Follow up Lost	06	11	0.1573
Died	01	02	0.5637
Failure	0	02	-
Treatment Regimen changed	0	01	-

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873 *Table 6: Impact of Treatment on weight*

Weight Status	<i>INH low concentration resistance</i> N=35	<i>Mean±SD</i>	<i>INH high concentration resistance</i> N=66	<i>Mean±SD</i>	p Value
Weight Gain	19 (54.3%)	(4.10±2.23 kg)	41(62.12%)	3.09±1.74	0.0622
Weight Lost	3 (8.6%)	(3±1 kg)	3(4.54%)	2.7±1.1	0.7247
No change	7 (20%)	-	8 (12.12%)	-	

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895